Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Vera Therapeutics, Inc. (VERA) had Cost of Goods Sold of $3.30M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$10.28M |
|
$-93.71M |
|
|
Cost of Goods Sold |
$3.30M |
$6.98M |
|
$105.98M |
|
$-95.70M |
|
$1.99M |
|
$-93.71M |
|
$-93.71M |
|
$-93.71M |
|
$-93.71M |
|
$-93.71M |
|
$-93.71M |
|
$-95.70M |
|
$-95.28M |
|
72.13M |
|
72.13M |
|
$-1.30 |
|
$-1.30 |
|
| Balance Sheet Financials | |
$441.29M |
|
-- |
|
$24.47M |
|
$465.75M |
|
$55.77M |
|
$75.43M |
|
$76.79M |
|
$132.57M |
|
$333.19M |
|
$312.69M |
|
$333.19M |
|
72.29M |
|
| Cash Flow Statement Financials | |
$-305.93M |
|
$-3.05M |
|
$9.57M |
|
$354.73M |
|
$55.32M |
|
$-299.40M |
|
$44.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.91 |
|
-- |
|
-- |
|
0.18 |
|
0.23 |
|
67.93% |
|
-931.23% |
|
-931.23% |
|
-- |
|
-911.85% |
|
-911.85% |
|
$-305.95M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
0.47 |
|
0.86 |
|
104.92 |
|
-28.13% |
|
-29.97% |
|
-20.12% |
|
-22.93% |
|
$4.61 |
|
$-4.24 |
|
$-4.24 |
|